Skip to main content

Table 5 Univariate and multivariate Cox regression analysis for overall survival (OS)

From: Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis

Factors

N

OS (months)

Univaritate

Multivariate

HR (95%CI)

p-value

HR (95%CI)

p-value

Age

  < 65

226

15.2

1.01 (0.78, 1.30)

0.964

–

–

  ≥ 65

188

15.7

1

   

Sex

 Male

287

16.0

0.93 (0.71, 1.21)

0.576

–

–

 Female

127

15.2

1

   

Smoking history

 Never

142

15.2

0.94 (0.70, 1.27)

0.686

–

–

 Ever

142

13.9

1

   

 Unknown

130

15.2

0.92 (0.66, 1.28)

0.610

–

–

Histology Subtype

 Squamous

79

15.2

1.16 (0.86, 1.58)

0.335

–

–

 Non-Squamous

335

15.2

1

   

Treatment Setting

 Clinical trial

161

16.4

0.84 (0.65, 1.09)

0.192

0.90 (0.69, 1.18)

0.450

 Non-clinical trial

253

14.7

1

 

1

 

Immunotherapy combination

 Monotherapy

322

15.2

1

 

1

 

 ICI + ICI

19

15.2

1.07 (0.60, 1.92)

0.819

1.20 (0.67, 2.18)

0.539

 ICI + Chemotherapy/other

73

16.0

0.89 (0.61, 1.29)

0.530

0.88 (0.61, 1.28)

0.512

irAEs

 Yes

98

18.2

0.70 (0.51, 0.94)

0.020

0.70 (0.51, 0.96)

0.028

 No

316

13.9

1

 

1

 
  1. N number of patients, OS overall survival, ICI immune checkpoint inhibitor, irAE immune related adverse events